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Summary  
Background. Infections by carbapenem-resistant Klebsiella pneumoniae (CRKp)  may represent a 
challenging problem in stem cell transplant (SCT) recipients.   However, little is known on their 
epidemiological and prognostic impact. 
Methods. A retrospective survey ( January 2010- July 2013) involving 52 Italian transplant centers 
was performed to assess the epidemiology of CRKp infections in autologous and allogeneic SCT 
and to analyze the factors associated to survival in patients with post-transplant CRKp infection. 
Findings. Cases of  CRKp infection  were reported in 22% of autologous and in 61% of allogeneic 
SCT centers. CRKp infections were documented in 26 autologous and 87 allogeneic SCTs, with an 
incidence of  0.4% (from 0.1% in 2010 to 0.7% in 2013) and 2% (from 0.4% in 2010 to 2.9% in 
2013) ,respectively.  A CRKp colonization documented before or after transplant was followed by  
a post transplant infection in 27.9% of autologous and 28.8% of allogeneic SCT patients. The 
overall mortality rate was 16%  in autologous and 70.1%  in allogeneic SCT patients with  CRKp 
infection. A CRKp infection documented before transplant (HR 0.33, 95% CI 0.15 – 0.74; p=0.007) 
and a not adequate first line antibiotic therapy  (HR 2.67, 95% CI 1.43 – 4.99; p=0.002) were 
independent factors associated with an increased mortality in allogeneic SCT patients. 
Interpretation. Our study shows  dramatic findings  of CRKp infections in SCT patients in Italy 
particularly after allogeneic SCT. The detection of carriers to implement isolation measures,   and 
the definition of  early, active  therapeutic strategies represent  critical aspects of the management of 






The increasing incidence of infections by carbapenem resistant Klebsiella pneumoniae (CRKp)  is a 
significant public health challenge worldwide (1,2). CRKp isolates have caused numerous infection 
outbreaks in United States, Israel, Greece, China and South America, and an increasing 
epidemiological impact has also been observed in Italy in the last few years (1-7).  
Infections caused by CRKp isolates are associated with high morbidity and mortality rates   
particularly in high risk  intensive care unit (ICU) and solid organ transplant (SOT) patients (8-14). 
Infection and colonization by these multiresistant bacteria may represent a challenging problem in 
stem cell transplant (SCT) recipients  not only for the management of post-transplant complications 
but also for the eligibility to transplant itself when patients acquire the pathogen before the 
transplant procedure (15,16).   However, little is known on the overall epidemiological and 
prognostic impact of these infections in the autologous and allogeneic SCT population. 
To assess the current epidemiology, clinical characteristics and outcome of CRKp 
colonization and infection in SCT patients,  the Gruppo Italiano Trapianto Midollo Osseo (GITMO) 
retrospectively collected data of  patients  undergoing allogeneic and autologous SCT during the 
period 2010-2013.  These data provide the basis for promoting direct efforts in the  management of 
CRKp infections  in the SCT population. 
 
 
Patients and methods 
The retrospective survey involved 52 transplant centers in Italy to assess the incidence of 
colonization and infection by CRKp isolates before and after SCT. Enrollment was limited to 
patients undergoing autologous or allogenic SCT during the period from January 2010  through July 
2013. Cases of CRKp infection or colonization documented in patients who relapsed and were 
submitted to further chemotherapy after SCT were not considered. 
Data collection. Each transplantation centre completed a questionnaire  reporting the number of 
allogeneic and autologous SCTs performed during the period of study at each centre, and the 
following data regarding patients with CRKp colonization or infection documented during the 3 
months before transplant and during the first year after transplant or until December 2013 when the 
data collection was frozen: patient’s demographic characteristics, diagnosis and phase of the 
underlying disease,  stem cell donor, pretransplant conditioning regimen and timing of colonization 
and/or infection before and after SCT. Information pertaining to the cases of CRKp infection 
included also time of onset of infection after transplant, site of infection, development of septic 
shock, details on first line and second line antibiotic therapy, survival at 3 months from infection 
and cause of death. First line antibiotic therapy was defined as the treatment administered at the 
onset of the febrile/infectious episode regardless of the following microbiological CRKp infection 
documentation. Any subsequent modification of the treatment, empirical or based on 
microbiological evidence, was considered a second line antibiotic therapy. 
Definitions. The following terms were defined prior to data collection and analysis. A CRKp 
colonization was defined as the isolation of the microorganism from any non sterile body site 
(usually respiratory tract/oral cavity, rectum, vagina, skin and urine) in absence of clinical findings 
suggestive of an infection. A proven CRKp infection was defined as the isolation of the 
microorganism from blood-cultures (at least 1 specimen) or other usually sterile body sites in 
association with clinical signs of the systemic inflammatory response syndrome (17). A probable 
CRKp infection was defined as the isolation of the microorganism from a non sterile body site (in 
particular respiratory and urinary tract) in presence of clinical signs of infection and of systemic 
inflammatory response syndrome, and after the exclusion of other possibly involved  etiologies.  
Onset of CRKp infection was defined as the date of collection of the first positive culture for proven 
cases  or of the clinical documentation of  the deep infection for probable cases. Septic shock was 
defined as sepsis associated with organ dysfunction and persistent hypotension despite volume 
replacement (17).  
Microbiology and antibiotic therapy. Each center was requested to report all cases of colonization 
and infection by K. pneumoniae  that exhibited minimum inhibitory concentrations (MICs) for 
imipenem and/or meropenem and/or ertapenem higher than 1 mg/L documented in the 3 months 
before and until one year after transplant.  Identification and susceptibility testing of the CRKp 
isolates were performed according to the local microbiologic methods used at each laboratory but 
no specific information was requested. We considered an adequate antibiotic therapy an association 
including at least two of colistin, tigecycline and gentamicin, with at least one of them active in 
vitro against the isolate (9). 
Ethical statement. This study was approved by the GITMO  Review Board and informed consent 
for the use of clinical data for scientific purposes was obtained from all  patients receiving SCT 
whose clinical data are regularly admitted in the GITMO databases. This was a non-interventional, 
retrospective, cohort study and the collection and storage of data were performed by the 
investigators directly involved in the patients’ care using current techniques of ensuring privacy; 
ethics committee approval was not, therefore, necessary.  
Analyses.  The aim of our study was to describe the incidence  of colonization and infection by 
CRKp isolates documented before (3 months)  and after (up to 12 months) SCT and the overall 
survival (OS) at 3 months of CRKp infections documented after SCT.  Mortality attributable to 
CRKp infection was defined as death occurred in patients who failed to respond to therapy and in 
patients with a partial response to therapy who died as the result of an acute event involving any of 
the sites of infection or of an unknown cause. OS was calculated from the documentation of a 
CRKp infection to the date of death or last follow-up. The outcome for survival was truncated at a 
3-months period of follow-up. Variables considered in the analysis of OS were: age (≤median years 
vs >median years), gender (male vs female),underlying disease (acute leukemia vs other diseases), 
phase of the underlying disease (remission or stable chronic vs active disease), type of donor  for 
allogeneic SCT (matched family vs haploidentical or unreleted volunteer or cord blood), 
conditioning regimen for allogeneic SCT (myeloablative vs non myeloablative of reduced 
intensity), CRKp colonization before transplant (no vs yes), CRKp infections before transplant (no 
vs yes),  level of CRKp infection documentation (proven vs probable), first line antibiotic therapy 
(adequate vs non adequate).  The probability of survival was calculated using the Kaplan-Meier 
estimate and a Kaplan Meier curve was generated to illustrate OS.  Univariate and multivariate Cox 
regression analyses were performed to evaluate the impact of the above variables on 3 month 
survival of the patients who developed CRKp infection after transplant. Variables that reached a P-
value of .20 after univariate analysis were included in the initial models and variables were 
eliminated one at a time in a stepwise fashion to only keep variables that reached a P value of .05 or 
less into the final models. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) 
were determined, and P values were calculated using the likelihood ratio test. Descriptive statistics 
included absolute and relative frequencies for categorical data, and median, mean and range for 
numerical measurements. The analyses were performed using SPSS software for Windows, version 
17.0.  
Results 
 Overall 6058 patients from 49 transplant centers and 4389 patients from 46 transplant 
centers received autologous and allogeneic SCT, respectively. They accounted for 54% of 
autologous SCTs and 72% of allogeneic SCTs performed in Italy during the study period (January 
2010 – July 2013) (www.gitmo.org).   
Isolation of CRKp (colonization or infection) after transplant was reported in 15 of 49 
(30.6%) autologous SCT centers and in 29 of 46 (63.0%) allogeneic SCT centers. In particular, 11 
of 49 (22.4%) autologous SCT centers and 28 of 46 (60.9%) allogeneic SCT centers documented at 
least one case of CRKp infection after transplant. There was no difference in the epidemiological 
distribution of CRKp in the transplant centers of north, middle and south of Italy.  
 The data on CRKp colonization and infection documented before and after SCT over the 
years are detailed in Table 1.  Overall, 26 and 87 cases of CRKp infection were reported 8 (+11.6 
days) median days from autologous and 15 (+ 83.6 days)  median days from allogeneic SCT, 
respectively. The incidence of CRKp infections was 0.4% (from 0.1% in 2010 to 0.7% in 2013) in 
autologous and 2% (from 0.4% in 2010 to 2.9% in 2013) in allogeneic SCT populations (Figure 1). 
Considering only the centers in which at least one CRKp infection was documented, the incidence 
was 1.2% (range 0.2 to 5%) and 2.6% (range 0.5 to 15.2%) of patients in autologous and allogeneic 
SCT centers, respectively.  The incidence of CRKp infections in children (age < 18 years) was 0.3% 
(1 of 376 transplants) in autologous SCT and 1.8% (15 of 820 transplants) in allogeneic SCT.  The 
characteristics of post-transplant CRKp infection cases are detailed in table 2. 
 The correlation between post transplant CRKp infections and previous CRKp isolation is 
detailed in table 3.  Overall, out of 43 autologous SCT and 73 allogeneic SCT patients with a CRKp 
colonization documented before or after transplant, 12 (27.9%) and 21 (28.8%) developed an 
infection, respectively. Recurrence of infection after transplant occurred in 1 of 3 (33.3%) and 10 of 
22 (45.4%) autologous and allogeneic SCT patients with an infection documented before transplant, 
respectively.  
The overall mortality rate at 3 months from the diagnosis of CRKp infection was 16% (4 of 
25 patients) in autologous SCT patients and 70.1% (61 of 87 patients) in allogeneic SCT patients 
(Figure 2). The mortality rate in children (age < 18 years) submitted to allogeneic SCT was 60% (9 
of 15 patients).  The CRKp infection was considered  the primary cause of death in all autologous 
SCT patients and in 56 (91.8%) allogeneic SCT patients who died, with an attributable mortality 
rate of 16% and 64.4%, respectively.  Out of 6 autologous and 43 allogeneic SCT patients who 
developed septic shock ,3 (50%) and 38 (88.4%) died due to the CRKp infection, respectively.    
 In multivariate analysis, a CRKp infection documented before transplant (HR 0.33, 95% CI 
0.15 – 0.74; p=0.007) and a not adequate first line antibiotic therapy  (HR 2.67, 95% CI 1.43 – 4.99; 
p=0.002) were independent factors associated with mortality. Also an active hematologic disease at 
transplant and an older age were associated to a poorer outcome, although not significantly (Table 
3).  No survival variable was statistically significant for autologous SCT in univariate analysis (data 
not shown). 
Discussion 
 The increasing resistance to carbapenems among K.pneumoniae has become a public health 
problem of major concern worldwide (1-3). In Europe, until 2009, the proportion of CRKp has 
remained overall low in most countries except Greece and Cyprus, where high-level endemicity has 
been reported since the mid-2000s (18). In Italy, sporadic cases or outbreaks caused by CRKp  have 
been reported since the early 2000s, but only since 2010 an abrupt and notable increase in the 
proportion of CRKp has been observed by the EARS-NET surveillance system (18), and shown to 
be mostly caused by the dissemination of strains producing KPC-type carbapenemases (7). Most of 
the case series of CRKp infections relate to ICU and SOT patients (9-14). SCT patients have been 
considered at risk for these severe infections too,  but only few information is specifically available 
regarding the incidence and prognostic factors in this population of immunocompromised subjects 
(15,16). 
 In consideration of the emerging morbidity and mortality for CRKp infections reported by 
some SCT Italian centers , the GITMO decided to investigate the phenomenon at national level with 
the aim to know the geographic epidemiology and the overall clinical and prognostic impact of this 
emerging complication in the autologous and allogeneic SCT populations. A prospective survey of 
severe gram negative infections involving most of GITMO transplant centers is ongoing 
(Clinicaltrials.GOV….),  but the rapidly growing epidemiological impact of CRKp infections 
prompted the GITMO to perform  a retrospective study  focused on CRKp colonization and 
infection in the SCT Italian population in order to obtain any information to clarify the 
epidemiological patterns and to early plan shared, tailored infection control strategies. The 
retrospective collection of the data and the lack of some microbiological information (i.e. molecular 
characterization of the isolates) are important limits of this study but  the involvement of a large, 
representative number of centers and the considerable number of CRKp infections reported 
represent a valuable characteristic of the survey.     
 As expected, there was a significantly different epidemiology of CRKp in the autologous 
and allogeneic SCT populations. Although an increasing trend of infections was observed also in 
autologous SCT patients since 2010,  the epidemiological impact of CRKp in this type of transplant 
seems to be quite favorable not only for the limited geographical spread (22% of autologous SCT 
centers from 6 regions reported at least 1 case of CRKp post-transplant infection) and the low 
overall incidence of the infection (0.4%),  but also for the  contained mortality rate (16%). The type 
of the underlying disease, mainly represented by chronic lymphoprolipherative malignancies, and of 
the chemotherapy treatment before transplant  usually administered in an outpatient setting  and the 
short period of post-transplant neutropenia probably represent the reasons for the favorable 
epidemiology of CRKp in the autologous SCT population.   
 Indeed, the dramatic findings observed in allogeneic SCT deserve a careful analysis. In line 
with the national data  reported by the EARS-NET surveillance system (18), a significant increase 
of cases of CRKp infection was observed in the last few years (from 0.4%  in 2010 to 2.9% in 
2013), and 60% of allogeneic transplant centers from 14 of the 20 italian regions documented at 
least one case of CRKp infection. Furthermore, the incidence reported for the transplants performed 
in 2013 may be underestimated considering the shorter follow-up period as compared to the 
previous years. Outbreaks involving a large proportion of patients (reaching 15% of transplants in 
one center) occurred  in some centers with a significant impact in the transplant related mortality  
rate.   
The most relevant data of our survey was represented by the infection-related mortality (64.4%) 
observed in allogeneic SCT patients, comparable or   higher than that reported in previous series of 
ICU ( 32-41%) and  SOT (0-71%) patients (9-14).  The analysis of the variables of survival 
demonstrated the independent impact of the history of an infection documented prior to transplant 
and of the adequacy of the first line antimicrobial therapy in the outcome of the patients.         
Retrospective studies in ICU patients have examined mortality in relation to antibiotic treatment for 
CRKp bloodstream infections and demonstrated that the use of combinations with appropriate 
antibiotics are associated with increased survival. Tumbarello and colleagues, while  reporting a 
crude 30-day mortality of 42% in 125 bloodstream infections due to CRKp, demonstrated that only 
the triple combination of colistin, tigecycline, and meropenem was associated with increased 
survival as compared to other treatments (9). Similarly, in the study by Zarkotou and colleagues, 
which included 53 bloodstream infections caused by CRKp, all patients who received appropriate 
combination treatment survived whereas patients treated with monotherapy—including colistin 
monotherapy— experienced a high infection-attributable mortality (47%) (10). In a further study, 
Qureshi and colleagues reported crude 28 day mortality of 13% and 58%  among patients treated 
with active combination and monotherapy, respectively (19).  
In our cases, an association of  at least two of colistin, tigecycline and gentamicin  (with at least one 
antibiotic active in vitro against the isolate) was administered in 31 (35.6%) allogeneic SCT patients 
since the first day of fever or at the onset of other clinical signs before the microbiological 
documentation of the CRKp infection. The use of a first line CRKp active treatment, which is not 
considered a standard empiric antibiotic therapy in hematologic patients,  was  driven by the 
documentation of a prior CRKp colonization or infection, or by the local epidemiology in some 
centers with an ongoing outbreak. In these patients the infection related mortality rate was 48% as 
compared to 73% in patients who received a not active first line antibiotic therapy. It was not 
possible to compare the efficacy of the different active antibiotic associations  (see table 2) due to 
the limited number of cases.  The recently published guidelines of the 4th European Conference on 
Infections in Leukemia (ECIL-4) on targeted therapy against multiresistant bacteria in leukemic and 
SCT recipients underline the need of the above  non-conventional agents as a treatment option of 
CRKp infections (20). The use of these associations should be based on  in vitro susceptibility data, 
and a careful assessment of the risk-benefit balance (20). However, our data seem to suggest that  
an early risk and epidemiology-driven antimicrobial strategy in the allogeneic SCT population may 
be required.   In view of the short median time of death (5 days) from the onset of the infection, a 
strategy leading to a tailored antibiotic treatment before the documentation of CRKp infection may 
be considered. On the other hand, the outcome of patients who received a first line active antibiotic 
therapy continued to be very poor. In particular, 9 of 10 (90%) patients with a CRKp infection 
documented before transplant and who developed a recurrence of the infection after transplant early 
died despite an active antibiotic therapy.  
 A predictive significance of colonization in the development of a CRKp infection was 
shown in our study in which nearly one-third  of patients with a CRKp colonization, documented 
before or after transplant, developed an infection. On the other hand, in a large number  of patients 
with a post-transplant infection no previous colonization was reported.  The difficulties in the 
detection of colonization may justify this finding, however, the lack of a well-defined colonization 
survey strategy  in several centers was probably the cause of an under-documentation of a CRKp 
colonization preceding the infection. This is a crucial point of the CRKp infection control strategy if 
we consider the importance of the knowledge of the colonization by multiresistant microorganisms 
in tailoring an early, active antibiotic therapy.  
In conclusion, our study shows  dramatic findings of CRKp infections in allogeneic SCT patients.  
The lack of treatments   active against this multiresistant pathogen represents a challenging issue 
also considering the paucity of new antibacterial drugs in the near future (20,21).The poor outcome 
observed also in patients who received a presumably effective first line antibiotic therapy makes it a 
priority to prevent infections with control measures. The detection of the carriers to implement 
isolation measures avoiding nosocomial transmission,   and to define  an early tailored therapeutic 
strategy represents a critical aspect of the management of CRKp infections in the SCT population 







1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M,Cornaglia, 
Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, 
Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N,Quinn 
JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae 
carbapenemases. Lancet Infect Dis. 2013;13:785-96. 
2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis 
of global dimensions. Clin Microbiol Rev. 2012 ;25:682-707. 
3. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore 
DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann 
P; European Network on Carbapenemases. Rapid evolution and spread of carbapenemases 
among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012 ;18:413-31.  
4. Giani T, D'Andrea MM, Pecile P, Borgianni L, Nicoletti P, Tonelli F, Bartoloni A, Rossolini 
GM. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 
Carbapenemase. J Clin Microbiol. 2009; 47:3793-4. 
5. Fontana C, Favaro M, Sarmati L, Natoli S, Altieri A, Bossa MC, Minelli S, Leonardis F, 
Favalli C. Emergence of KPC-producing Klebsiella pneumoniae in Italy. BMC Res Notes. 
2010 ;3:40. 
6. Gaibani P, Ambretti S, Berlingeri A, Gelsomino F, Bielli A, Landini MP, Sambri V. Rapid 
increase of carbapenemase-producing Klebsiella pneumoniae strains in a large Italian 
hospital: surveillance period 1 March - 30 September 2010. Euro Surveill. 2011;16(8). 
7. Giani T, Pini B, Arena F, Conte V, Bracco S, Migliavacca R; AMCLI-CRE Survey 
Participants, Pantosti A, Pagani L, Luzzaro F, Rossolini GM. Epidemic diffusion of KPC 
carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide 
survey, 15 May to 30 June 2011. Euro Surveill. 2013;18(22). 
8. Mammina C, Bonura C, Di Bernardo F, Aleo A, Fasciana T, Sodano C, Saporito MA, Verde 
MS, Tetamo R, Palma DM. Ongoing spread of colistin-resistant Klebsiella pneumoniae in 
different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill. 
2012;17(33).  
9. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, 
Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. Predictors 
of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-
producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 
55:943-50.  
10. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, 
Themeli-Digalaki K, Tsakris A. Predictors of mortality in patients with bloodstream 
infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate 
antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798-803.  
11. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, 
Barbosa V, Abboud CS Infection with Klebsiella pneumoniae carbapenemase (KPC)-
producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012 ;14:198-
205.  
12. Taglietti F, Di Bella S, Galati V, Topino S, Iappelli M, Petrosillo N. Carbapenemase-
producing Klebsiella pneumoniae-related mortality among solid organ-transplanted patients: 
do we know enough? Transpl Infect Dis. 2013 ;15:E164-5. 
13. Kalpoe JS, Sonnenberg E, Factor SH, del Rio Martin J, Schiano T, Patel G, Huprikar S. 
Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver 
transplant recipients. Liver Transpl. 2012 ;18:468-74.  
14. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, 
Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth 
BN, Hong Nguyen M. Epidemiology and molecular characterization of bacteremia due to 
carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 
2013;13:2619-33.  
15. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: 
epidemiology and prevention. Clin Infect Dis. 2011;53:60-7. 
16. Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, Oren I. SCT 
in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience 
with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 
2011;46:1226-30. 
17. Russell JA . Management of sepsis. N Engl J Med 2006;355:1699-713 
18. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance 
surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance 
Surveillance Network (EARS-Net). Stockholm: ECDC; 2012. Available from: 
http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-
surveillance-europe-2012.pdf 
19. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, 
Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing 
Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob 
Agents Chemother. 2012;56:2108-13. 
20. Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, Gyssens IC, 
Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M; ECIL4, a joint venture of 
EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-
resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines 
of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 
2013 ;98:1836-47. 
21. Crunkhorn S. Antibacterial drugs: New antibiotics on the horizon? Nat Rev Drug Discov. 
2013 ;12:99. 
22. Giani T, Tascini C, Arena F, Ciullo I, Conte V, Leonildi A, Menichetti F, Rossolini GM. 
Rapid detection of intestinal carriage of Klebsiella pneumonia producing KPC 
carbapenemase during an outbreak. J Hosp Infect. 2012 ;81:119-22.  
23. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a 
country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals 
via a nationally implemented intervention. Clin Infect Dis. 2011;52:848-55. 
24. Landman D, Babu E, Shah N, Kelly P, Olawole O, Backer M, et al. Transmission of 
carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J 
Antimicrob Chemother. 2012;67:1427-31.  
25. Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, 
Di Paolo A, Ripoli A, Lewis R, Rossolini GM, Menichetti F; the GENGUT study group. 
Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella 
pneumoniae infections: the relevance of concomitant systemic antibiotic therapy. 













Participants of the GITMO survey 
1. Divisione di Ematologia, Azienda Ospedaliera Papa Giovanni XXIII,  Bergamo (Marco 
Frigeni, Alessandro Rambaldi) 
2. Unità operative di Ematologia e Trapianto Midollo Osseo, Ospedale San Raffaele, Milan 
(xxx, Fabio Ciceri) 
3. Centro Trapianti di Midollo  Ospedale Maggiore IRCCS, Milan  (xxx, Claudio Annaloro) 
4. ISTITUTO CLINICO HUMANITAS; Rozzano, Milano (xxx, Luca Castagna)  
5. Unità Operativa di Ematologia,  Azienda Spedali Civili, Brescia (Giuseppe Rossi, Chiara 
Cattaneo)  
6. Unità  Trapianti di Midollo Osseo per Adulti, Azienda Spedali Civili, Brescia (Domenico 
Russo, Cancelli)  
7. Dipartimento di Ematologia Oncologica, Fondazione Istituto di Ricovero e Cure a Carattere 
Scientifico Policlinico San Matteo, University of Pavia, Pavia (xxx, Alessandrino Emilio 
Paolo) 
8. UO Centro Trapianto Midollo Osseo – Fondazione MBBM , Monza (xxx, Attilio Rovelli) 
9. Dipartimento di Oncologia ed Ematologia A.O. Citta' della Salute e della Scienza di Torino, 
P.O. Molinette, Turin (xxx, Alessandro Busca)  
10. S.C. Oncoematologia Pediatrica e Centro Trapianti OIRM, Turin  (Francesca Carraro, 
Franca Fagioli) 
11. Unità clinica FPO/IRCCs di Candiolo Centro Metropolitano di Torino (xxx, Fabrizio 
Carnevale)  
12. SCDU Medicina Interna II – Ematologia, AOU San Luigi Gonzaga, Orbassano, Torino 
(Marco De Gobbi, Giuseppe Saglio)  
13. Divisione di Ematologia Azienda Ospedaliera S.Croce e Carle, Cuneo (xxx, Nicola Mordini)  
14. SCDU Ematologia, AOU Maggiore della Carità, Novara ( xxx, Luca Nassi ) 
15. Dipartimento di Ematologia, Ospedale San Bortolo, Vicenza (xxx, Roberto Raimondi) 
16. Ospedale dell’Angelo, Mestre, Venezia; (Michele Vespignani, Renato Bassan) 
17. Unità di Oncoematologia Pediatrica, Azienda Ospedaliera Universitaria Integrata, Verona 
(xxx, Simone Cesaro) 
18. Clinica Ematologia - Azienda Ospedaliera-Universitaria, P.le S. Maria della Misericordia, 
Udine  (xxx, Francesca Patriarca) 
19. Divisione di Ematologia II,  IRCCS S. Martino University Hospital – IST, Genoa (Andrea 
Bacigalupo, Annamaria Raiola)   
20. Divisione Malattie Infettive e Unità di Trapianto di Midollo Osseo- Istituto Giannina 
Gaslini, Genoa (Elio Castagnola, Edoardo Lanino)  
21. Istituto di Ematologia e Oncologia Medica, L. e A Seragnoli, Policlinico S.Orsola Malpigli, 
Bologna (Marta Stanzani, Giuseppe Bandini) 
22. Programma di Oncologia, Ematologia e Trapianto di CSE, U.O. Pediatria-Prof. Pession, S. 
Orsola-Malpighi, University of Bologna, Bologna (xxx, Arcangelo Prete)  
23. Ospedale Civile di Piacenza, 1a Divisione Medica Onco-Ematologia, Piacenza (xxx, 
Daniele Vallisa)  
24. Ematologia e Centro Trapianti Midollo Osseo, Ospedale Maggiore, Parma (Cecilia 
Caramatti, Franco Aversa).  
25. UO Ematologia – Ospedale Santa Maria delle Croci, Ravenna (xxx, Eliana Zuffa) 
26.  Cattedra di Ematologia, Azienda Ospedaliera di Careggi, Florence (Stefano Guidi, Alberto 
Bosi)  
27. AOU Meyer Children Hospital Medical Direction, Florence (xxx, Veronica Tintori) 
28. Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, 
Azienda Policlinico Umberto I, Sapienza University of Rome, Rome (Anna Paola Iori, 
Saveria Capria)   
29. Fondazione Policlinico Tor Vergata, Unità di Trapianto Cellule Staminali, University Tor 
Vergata, Rome  (Laura Cudillo, William Arcese) 
30. Divisione di Ematologia, Ospedale S.Eugenio, Rome (Teresa Dentamaro, Paolo De 
Fabritiis)   
31. Unità Operativa di Ematologia, Azienda Ospedaliera San Giovanni Addolorata, Rome (xxx, 
Anna Chierichini) 
32. UOC di Ematologia, Ospedale S Andrea, Rome (xxx, Antonella Ferrari) 
33. Clinica di Oncologia ed Ematologia, IFO – Istituto Regina Elena, Rome (xxx, Andrea 
Mengarelli) 
34. Divisione di Ematologia, Università Campus Biomedico, Rome (Elisabetta Cerchiara, 
Giuseppe Avvisati). 
35. Istituto Mediterraneo di Ematologia, Policlinico Tor Vergata,  Rome (xxx, Javid Gaziev) 
36. UOC di Ematologia e Trapianti di Cellule Staminali, Az. Osp. S.Camillo-Forlanini, Rome; 
(Alessandro Severino, Ignazio Majolino) 
37. Divisione di Ematologia- Istituto di Ematologia, Policlinico A. Gemelli, Università Cattolica 
S. Cuore, Rome; (Patrizia Chiusolo, Simona Sica)  
38. Unità Operativa di Oncoematologia, Ospedale pediatrico Bambino Gesù, Rome (Alice 
Bertaina, Franco Locatelli) 
39. Trapianto di Midollo Osseo Ospedale Santa Maria della Misericordia; Perugia (Maria 
Speranza Massei , Alessandra  Carotti)  
40. S.C. ONCOEMATOLOGIA PEDIATRICA, Perugia (Katia Perruccio, Maurizio Caniglia) 
41. UOC  di Trapianto Emopoietico, Ospedale Spirito Santo, Pescara; (Stella Santarone, Paolo 
Di Bartolomeo) 
42. UOC di Ematologia, Ospedale C e G Mazzoni, Ascoli Piceno; (Serena Mazzotta, Piero 
Galieni) 
43. Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, 
Ancona, (xxx, Attilio Olivieri) 
44. Ematologia, Dipartimento di medicina e chirurgia, Universita degli  studi di Napoli Federico 
II; Naples (xxx, Antonio Risitano)  
45. Sezione di Ematologia, Dipartimento di Emergenza e Trapianto d’Organo, University of 
Bari; (xxx, Domenico Pastore) 
46. Divisione di Ematologia con Unità di Trapianto di Midollo- Ospedale S.G. Moscati, Taranto 
(xxx, Giovanni Pisapia) 
47. Divisione di Ematologia Centro Unico Regionale TMO e Terapie Emato-Oncologiche 
Sovramassimali "A. Neri" Ospedale Bianchi-Melacrino-Morelli, Reggio Calabria (xxx, 
Giuseppe Irrera)  
48. Centro Trapianti "Wilma Deplano"  Ospedale oncologico Armando Businco, Cagliari (xxx, 
Donatella Baronciani) 
49. Ematologia - Centro trapianti di midollo osseo , P.O. " R. Binaghi", Cagliari (xxx, Adriana 
Vacca)  
50. U.O di Oncoematologia e TMO Dip. Oncologico La Maddalena, Palermo (xxx, Maurizio 
Musso)  
51. UOC di Ematologia, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo (xxx, Rosanna 
Scimè) 
52. Cattedra di Ematologia - Ospedale Ferrarotto, Univ. degli Studi di Catania, Catania; (xxx, 





Figure 1. Incidence of post-transplant CRKp infections in autologous and allogeneic SCT patients. 
 
Incidence in 2013 possibly underestimated due to the shorter post-transplant follow-up period as 
compared to the previous years 
 
 
Figure 2. Overall survival of patients with CRKp infection documented after allogeneic SCT 
 
Table 1. Cases of colonization and infection by CRKp isolates documented in the 3 months before 
and in the 12 months after autologous and allogeneic SCT 
 















SCT, n. of cases (% of 
SCT) 
0 (0) 1(<0.1) 5 (0.3) 7 (0.6) 13 (0.2) 
Infection before SCT, n. 
of cases (% of SCT) 
0 (0) 1 (<0.1) 0 (0) 2 (0.2) 3 (<0.1) 
Colonization after SCT#, 
n. of cases (% of SCT) 
6 (0.4) 5 (0.3) 8 (0.5) 11 (1.0) 30 (0.5) 
Infection after SCT*, n. 
of cases (% of SCT) 
2(0.1) 10 (0.6) 5 (0.3) 8 (0.7) 25 (0.4) 
Centers with at least one 
case of infection after 
SCT, n. (% of 49 
centers) 
1(2) 7 (14.3) 4(8.2) 5(10.2) 11(22.4) 















SCT, n. of cases (% of 
SCT) 
0 (0) 10 (0.8) 13 (1) 9 (1.2) 32 (0.7) 
Infection before SCT, n. 
of cases (% of SCT) 
0 (0) 3 (0.2) 11 (0.9) 8 (1.0) 22 (0.5) 
Colonization after SCT#, 
n. of cases (% of SCT) 
1 (<0.1) 7 (0.6) 16 (1.3) 17 (2.2) 41 (0.9) 
Infection after SCT*, n. 
of cases (% of SCT) 
5 (0.4) 26 (2.1) 34 (2.7) 22 (2.9) 87 (2.0) 
Centers with at least one 
case of infection after 
SCT, n. (% of 46 
centers) 
3(6.5) 16 (34.8) 15 (32.6) 16 (34.8) 28 (60.9) 
# Patients with colonization or infection documented before transplant excluded   
* In allogeneic SCT, the incidence of CRKp infections (p=0.0004) and the rate of centers with at 
least one documented case (p=0.001) significantly increased from 2010 to 2011. In autologous 
SCT, the incidence of CRKp infections increased not significantly in the years while the rate of 
centers with at least one documented case significantly increased from 2010 to 2011 (p=0.03). 
^ Incidence in 2013 possibly underestimated due to the shorter post-transplant follow-up period as 





Table 2. Characteristics of patients with CRKp infection documented after autologous and 
allogeneic SCT. 




Male sex, n. (%) 17 (68) 50 (57) 
Age, years, median + SD 55 + 14.6 43 + 17.9 
Children , < 18 years, n. (%) 1 (4) 15 (17.2) 
Underlying disease, n. of cases (%) 
  Acute myeloid leukemia 
  Acute lymphoid leukemia 
  Non Hodgkin lymphoma 
  Hodgkin lymphoma 
  Multiple myeloma 
  Myelodisplastic syndrome 
  Chronc myeloprolipherative disease 
  Aplastic anemia 





















Phase of the underlying disease, n. of cases % 
 I complete remission 
 >II complete remission 












Type of donor, n. of cases (%) 
 Matched related 
 Haploidentical 
 Unrelated volunteer 








Type of conditioning regimen, n. of cases (%) 
Myeloablative 







Time of onset from SCT, median days + SD 8 + 11.6 15 + 83.6 









Site of infection 
 Blood only  
 Blood plus lung 
 Blood plus skin 
 Bloos plus gut 
 Skin 















Septic shock 6 (24) 43 (49.4) 
Adequate first line antibiotic therapy@ 
 Tigecycline – gentamicin (+- meropenem) 
 Colistin – gentamicin (+- meropenem) 
 Colistin – tigecycline – gentamicin  (+-meropenem) 











Overall mortality at 3 months, no of cases (%) 4 (16) 61 (70.1) 
Deaths attributed to CRKp infection, n. of cases (%) 4 (100) 56 (91.8) 
NA: not applicable; # after engraftment in 35 cases (40%) 
*all cases of pulmonary infiltrate with CRKp isolation from respiratory tract and no evidence of 
other pathogens. 
@ First line antibiotic therapy was considered adequate if included at least two of colistin, 






Table 3. Correlation between CRKp post transplant infections and previous CRKp isolation  
Type ant timing of CRKp 
isolation 
No. of post transplant infections /no. of pts with previous 
isolation (%) 
 Autologous SCT Allogeneic SCT 
Colonization before transplant 3/13(23.1) 10/32 (31.2) 
Infection before transplant 1/3 (33.3) 10/22 (45.4) 
Colonization after transplant 9/30 (30) 10/41 (24.4) 
Table 4. Probability of Overall Survival at 3 months from  CRKp infection in 87 allogeneic SCT patients 
 OS, % Univariate Multivariate 
HR (95% CI) P HR (95% CI) P 
Male vs Female 28 vs 32 1.04 (0.62-1.73) 0.88   
Age , < 43 years vs > 43 years 37 vs 22 0.67 (0.40-1.10) 0.11 0.59 (0.34-1.01) 0.056 
Underlying disease, acute leukemia vs other 27 vs 35 1.30 (1.30-0.76) 0.33   
Status of the underlying disease at transplant,  Complete remission/stable vs active 36 vs 18 0.56 (0.33-0.44) 0.03 0.61 (0.35 – 1.06) 0.080 
CRKp colonization before transplant, No vs yes  * @ 30 vs 50 1.76 (0.70-4.43) 0.23   
CRKp infection before transplant, No vs yes * 32 vs 10 0.51 (0.25-1.04) 0.06 0.33 (0.15 – 0.74) 0.007 
Myeloablative conditioning yes vs no 29 vs 32 1.22 (0.74-2.03) 0.44   
Donor type 
Matched related vs mismatched related or unrelated volunteer donor or cord blood  
31 vs 28 0.95 (0.56-1.61) 0.85   
Level of CRKp infection documentation, proven vs probable 31 vs 20 0.89 (0.42-1.87) 0.76   
First line antibiotic therapy,  Not adequate vs adequate 
 
21 vs 45 1.76 (1.05-3.10) 0.04 2.67 (1.43 – 4.99)  
0.002 
 
*During the 3 months preceding SCT 
 
@Ten patients with a previous CRKp infection excluded. 
 
 
 
